#USA #New York #FDA Compliance #Unicycive Therapeutics #UNCY

Unicycive Therapeutics Under Fire: Fraud Allegations and Shareholder Impact

In a shocking development for investors, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently embroiled in a securities class action lawsuit, sparked by potential misconduct by its top executives, including CEO Shalabh Gupta and CFO John Townsend. The complaint, filed on behalf of shareholders who purchased securities between December 29, 2025, and June 29, 2026, contends that the two executives misled shareholders by providing unfounded assurances regarding the company’s third-party manufacturing processes and their compliance with FDA regulations.

The lawsuit highlights significant concerns regarding the efficacy of Unicycive’s communication with its investors, specifically alleging that both Gupta and Townsend failed to conduct necessary inspections of a critical vendor involved in the company’s drug manufacturing. During the relevant period, Unicycive had publicized that this vendor was making “significant progress” toward meeting FDA standards. However, according to the claims, the company did not independently verify these assertions through any inspection, raising serious questions about the integrity of their financial disclosures.

On June 30, 2026, Unicycive’s stock took a staggering hit, plummeting by over 39% from $7.70 to $4.69 per share after the company announced it had received a second Complete Response Letter from the FDA. This letter cited persistent deficiencies concerning the same manufacturing practices previously flagged, undoubtedly shaking investor confidence and leading to the legal proceedings now underway.

The Basis of the Allegations

The crux of the lawsuit draws attention to the plausible responsibility of both Gupta and Townsend due to their authoritative roles within the organization. As individuals who signed off on the company’s SEC filings, they are perceived to have a legal obligation to ensure that all material facts were disclosed fully and accurately. The Sarbanes-Oxley Act requires such officers to certify their financial disclosures personally, adding another layer of accountability. Furthermore, the allegations suggest that there was a fundamental breach in these responsibilities involving critical statements tied to the company's regulatory compliance.

Notably, the filing points to the failure of Unicycive to conduct its own audit of the vendor's facility, which it had reported as compliant. Such neglect, the suit proposes, constitutes grounds for control person liability under Section 20(a). This provision holds executive officers accountable for the actions of the corporation when they are found to have significantly influenced or controlled the company’s operations or disclosures.

Legal Proceedings and Shareholder Rights

The deadline to apply as a lead plaintiff in this class action case is set for November 2, 2026. This means that shareholders who suffered losses during the class period can still consider participating in the legal action and potentially recover their losses. However, even those who have recently sold their shares may retain eligibility if they purchased during the specified timeframe. Interested investors should collect brokerage records demonstrating their purchases to facilitate a comprehensive evaluation, as even former shareholders may qualify to seek damages.

According to Joseph E. Levi, a principal attorney involved in the case, shareholder rights and corporate accountability form a cornerstone of the lawsuit. He stated, “Investors are entitled to trust the disclosures made by the company and deserve to pursue accountability for instances where they feel misled.”

As this case unfolds, it will undoubtedly stay at the forefront of conversations concerning corporate governance and transparency in the biotech sector. Investors keen on following developments should remain vigilant and consider the implications of the rulings on their investments and broader market confidence in biotech stocks.

Should you wish to learn more about your rights as a shareholder in this case, you can contact Levi Korsinsky LLP at (888) SueWallSt for a consultation and further guidance on how to proceed.

In conclusion, the Unicycive case serves as a stark reminder of the importance of transparent corporate practices and the possible repercussions when that trust is broken.